Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al
Annals of the rheumatic diseases.
2016 Jul ;
75 (7) :
e38.
[epub] 20160504
Language English Country United States Media print-electronic
Document type Letter, Comment
Persistent link
https://www.medvik.cz/link/pmid27147708
PubMed
27147708
DOI
10.1136/annrheumdis-2016-209517
PII: S0003-4967(24)01810-7
Knihovny.cz E-resources
- Keywords
- Disease Activity, Rheumatoid Arthritis, Treatment,
- MeSH
- Antirheumatic Agents MeSH
- Biosimilar Pharmaceuticals * MeSH
- Etanercept * MeSH
- Immunoglobulin G MeSH
- Receptors, Tumor Necrosis Factor MeSH
- Arthritis, Rheumatoid MeSH
- Publication type
- Letter MeSH
- Comment MeSH
- Names of Substances
- Antirheumatic Agents MeSH
- Biosimilar Pharmaceuticals * MeSH
- Etanercept * MeSH
- Immunoglobulin G MeSH
- Receptors, Tumor Necrosis Factor MeSH
References provided by Crossref.org
Rheumatology (Oxford, England).
2017 Dec 01 ;
56 (12) :
2093-2101.
